In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction. Full trial results and Plain Language Summary: https://t.co/6CYFFJRbBZ https://t.co/8NFiVBRbqg
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Sep 2024 – Nov 2025Where it's discussed
-
X / Twitter230 posts
-
News81 articles
-
YouTube17 videos
-
Blogs9 articles
-
Facebook5 posts
-
Bluesky1 posts
AI synopsis
What people are saying
The overall tone indicates strong recognition of finerenone's potential benefits, with many posts citing trial statistics like the reduction in worsening heart failure events and emphasizing the significance of these results for heart failure management. Words such as 'promising,' 'breakthrough,' and 'exciting' reflect enthusiasm about the publication's contributions and possible shifts in treatment approaches.
Most discussions recognize the positive findings of the study, indicating general agreement on its importance.
Posts show high interest, with many referencing specific trial results, ongoing debates, and future implications.
Comments include detailed analysis, comparisons with existing treatments, and discussions about clinical applications, reflecting moderate engagement.
The discussions suggest this study could influence clinical practice and future research, highlighting its high impact.
Abstract in brief
- Steroidal mineralocorticoid receptor antagonists help patients with heart failure and reduced ejection fraction, but their effectiveness in those with mildly reduced or preserved ejection fraction is unclear, indicating a need for further research on finerenone.
- In a double-blind study, patients with heart failure (ejection fraction 40% or greater) were assigned to receive either finerenone or a placebo to assess its impact on heart failure events and cardiovascular death.
- Results showed that finerenone led to fewer worsening heart failure events and a lower overall rate of primary outcome events compared to placebo, although it also carried a higher risk of hyperkalemia.
Top posts
Most liked on X and BlueskyOriginal Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFFJRbBZ Editorial: FINEARTS-HF — The Latest Masterpiece for MRAs in Heart Failure https://t.co/dquTfwTvKa #Cardiology https://t.co/MNUUnL4PBC
The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart failure events. Is this an exciting breakthrough for these patients or just a more expensive me-too drug? #whatsnewwednesday https://t.co/dBGStfaIxW
FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite of total worsening heart failure events & death from CV causes vs. placebo ca. 2024 from @NEJM #Nephpearls #Cardiorenal
Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo https://t.co/ACWOXh6QNp https://t.co/4h2XOvZ0Wn
All mentions
Finerenone: New Treatment Option for Heart Failure with Preserved Ejection Fraction
This video explores the potential of finerenone as a treatment for heart failure with mildly reduced or preserved ejection fraction, highlighting recent clinical trial findings on its effectiveness in reducing heart…
Evaluating Finerenone for Heart Failure with Preserved Ejection Fraction
This video explores the potential benefits of finerenone in treating patients with heart failure and ejection fraction of 40% or greater, highlighting a double-blind study that showed reduced heart failure events and…
Nephroprotection Strategies for Chronic Kidney Disease Focused on 2025 Goals
Dr Doreen Zhu and Dr Parminder Judge discuss current and future approaches for protecting kidney health in chronic kidney disease patients, highlighting the EASiKIDNEY trial testing new treatments like vicadrostat…
Finerenone in Heart Failure with Preserved Ejection Fraction Insights
This video discusses the effectiveness of finerenone in treating heart failure with mildly reduced or preserved ejection fraction, highlighting recent research on its impact on heart failure events and cardiovascular…
Reevaluating Beta-Blocker Use in Myocardial Infarction with Preserved Heart Function
This video reviews recent clinical trials on beta-blockers after MI with preserved ejection fraction, highlighting no significant benefit in reducing death or MIs based on a large international study over 3.5 years.
Finerenone's Impact on Heart Failure with Preserved Ejection Fraction
This week in cardiology, we discuss renal denervation, the obesity paradox, and the FINEARTS trial of finerenone in HFpEF, highlighting its potential to reduce heart failure events and cardiovascular death while noting…
Evaluating Finerenone's Effectiveness in Mildly Reduced Heart Failure
Finerenone's Role in Heart Failure with Mildly Reduced Ejection Fraction
This episode discusses the expanding FDA approval of Finerenone for heart failure patients, including recent trial results showing reduced heart failure events with its use in patients with mildly reduced or preserved…
Finerenone Lowers Heart Failure Events in Preserved Ejection Fraction Patients
Ref httpswwwnejmorgdoi101056NEJMoa2407107. Finerenone reduces worsening heart failure events and cardiovascular death in patients with mildly reduced or preserved ejection fraction, demonstrating potential benefits in…
Finerenone for Heart Failure with Preserved Ejection Fraction
This clinical trial assessed finerenone's benefits in reducing heart failure events in patients with maintained or mildly reduced ejection fraction. Results indicate fewer heart failure worsening events but a higher…
Finerenone's Role in Heart Failure with Preserved Ejection Fraction
This video discusses the potential advantages of finerenone over steroidal MRAs, including its selectivity and potency, and reviews clinical trial findings on its impact on heart failure with preserved ejection…
#Фінеренон відкриває нові можливості у лікуванні #серцевої_недостатності з помірно зниженою
S3 Episode 4: Heart Failure, Incretin Therapies, and Type 2 Diabetes
Medical Portfolio Podcast: Best of the Month - August 2024
HEART FAILURE For Interns
The Rounds Table - Episode 123 - Trial Files Top 5 RCTs
The Rounds Table Throwback - Episode 99 - The Top 5 Papers of 2024
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF No significant heterogeneity was found on the effect of finerenone to reduce primary outcome events. Still, adverse https://t.co/b8myKXs8Oi
RT @abdelhamed012: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS‐HF - Ferreira - European Journal of Heart Failure - Wiley Online Library https://t.co/ez1N4Ystaj
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF No significant heterogeneity was found on the effect of finerenone to reduce primary outcome events. Still, adverse https://t.co/DbM9e2MpdG
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS‐HF - Ferreira - European Journal of Heart Failure - Wiley Online Library https://t.co/PTF9oJglpz
Finerenona en Insuficiencia cardíaca con FEVI moderadamente reducida y preservada FINEARTS-HF 10.1056/NEJMoa2407107 https://t.co/cCkHiwBkin
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @EJHFEiC:
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS‐HF https://t.co/RPpfRBtLx2
RT @drbennisahmed: Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved eject…
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF No significant heterogeneity was found on the effect of finerenone to reduce primary outcome events. Still, adverse https://t.co/dwhR7GYQYV
RT @gunnar_heine: EASi Kidney: First Patient Randomised in MARKUS Krankenhaus Frankfurt
RT @gunnar_heine: EASi Kidney: First Patient Randomised in MARKUS Krankenhaus Frankfurt
EASi Kidney: First Patient Randomised in MARKUS Krankenhaus Frankfurt
RT @toki_wo_koe: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/K9OnW6ip41
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/3cphzEGD6H
RT @mvaduganathan:
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes TOP TEN 2024 semaglutide led to larger…
RT @drbennisahmed: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes TOP TEN 2024 semaglutide led to larger…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes TOP TEN 2024 semaglutide led to larger…
RT @drbennisahmed: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes TOP TEN 2024 semaglutide led to larger…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a sig…
RT @drbennisahmed: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes TOP TEN 2024 semaglutide led to larger…
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes TOP TEN 2024 semaglutide led to larger reductions in heart failure–related symptoms and physical limitations and greater weight loss than placebo at 1 year https://t.co/ACWOXh6QNp https://t.co/8zz9v2IgZW
Finerenone in Heart Failure with Mildly Reduced or HFPEF Top Ten 2024 In HFmREF or HFPEF finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo https://t.co/ACWOXh6QNp https://t.co/4h2XOvZ0Wn
2/ FINEARTS-HF: Finerenone in HFpEF/mrEF reduced worsening HF events (RR 0.82, p=0.006) but had no significant effect on CV death. Promising, but monitor hyperkalaemia risk! ⚠️ #HFpEF
FINEARTS-HF試験 https://t.co/TOwe5xekBB 先日投稿したフィネロンの論文 フィネレノンはLVEF≥40%の心不全患者 心不全増悪+CV死亡の複合イベントを有意に減少 (RR 0.84, 95%CI: 0.74 to 0.95) 低カリウム血症リスクを低減、高カリウム血症リスク増加mildly reduced HFrEFやHFpEF症例に良いかも https://t.co/wWES8dPCNu
RT @dr_ukio: 【フィネレノンがEF≧40の心不全のHF増悪抑制(NEJM)】 FINEARTS-HF試験 世界37カ国、HFmrEF/HFpEFの症状あり心不全6016人32カ月 フィネレノン vs プラセボで 心不全増悪・心血管死は 0.84(0.74-0.95…
Full text links Finerenona en la insuficiencia cardíaca con fracción de eyección levemente reducida o preservada | New England Journal of Medicine https://t.co/tVCptDCb8b https://t.co/8rAZXxhLit
Acceso en
1. https://t.co/cPgNPcAHw4 2. https://t.co/zyZSTJLixN 3. https://t.co/mouYm7Rz3E 4. https://t.co/6QvXhBvEPp 5. https://t.co/DjmSDlzazE 6. https://t.co/AwbRdVjVYy 7. https://t.co/D1gzJbxE5u
RT @gunnar_heine: Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY Dr Doreen Zhu Dr Parminder Judge @AKronbichler @MarkusAtHome @MarcusSa…
RT @gunnar_heine: Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY Dr Doreen Zhu Dr Parminder Judge @AKronbichler @MarkusAtHome @MarcusSa…
RT @gunnar_heine: Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY Dr Doreen Zhu Dr Parminder Judge @AKronbichler @MarkusAtHome @MarcusSa…
RT @gunnar_heine: Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY Dr Doreen Zhu Dr Parminder Judge @AKronbichler @MarkusAtHome @MarcusSa…
RT @MarkusAtHome: Join our new webinar NOW on YouTube! Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY with our guests @doreen_zhu & Dr.…
RT @gunnar_heine: Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY Dr Doreen Zhu Dr Parminder Judge @AKronbichler @MarkusAtHome @MarcusSa…
Join our new webinar NOW on YouTube! Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY with our guests @doreen_zhu & Dr. Parminder Judge https://t.co/3jsuZzp06T Moderators: Prof. Dr. Johannes Mann, @gunnar_heine, @MarcusSaemann
Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY Dr Doreen Zhu Dr Parminder Judge @AKronbichler @MarkusAtHome @MarcusSaemann @NDTsocial @dgfn_ev @hjanders_hans https://t.co/OyFRCpRjOS via @YouTube
RT @Saludteca: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/lhe1ys2049
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/lhe1ys2049
RT @RealTNagasawa: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https:/…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/l1qBi7fIEG
RT @DrDamluji: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: @NEJM
RT @MarkusAtHome: TOP 10: ASi in CKD by Drs. @KatherineTuttl8, @P_Rossing et al. https://t.co/lQ8Gou4V7J The aldosterone synthase inhibi…
RT @MarkusAtHome: TOP 10: ASi in CKD by Drs. @KatherineTuttl8, @P_Rossing et al. https://t.co/lQ8Gou4V7J The aldosterone synthase inhibi…
TOP 10: ASi in CKD by Drs. @KatherineTuttl8, @P_Rossing et al. https://t.co/lQ8Gou4V7J The aldosterone synthase inhibitor vicadrostat dose-dependently reduced albuminuria without unexpected safety signals in CKD patients. Join our Webinar on 24th Jan. https://t.co/1EFJuiLsRJ https://t.co/BzHhuL9mET
RT @JuliaSellerm:
SUMMIT-HF - trial for tirzepatide in HFpEF https://t.co/kPYpKZVs9h FINE-Arts- Finerenone in HFmrEF and HFpEF https://t.co/sAZdsHTfrS
RT @JuliaSellerm:
2024 best publications in heart failure Palme d’or 2024 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction finerenone significantly lower rate of a composite of total WHF events and death from cardiovascular causes https://t.co/ACWOXh7oCX https://t.co/JCzgrBsuJa
RT @JuliaSellerm:
RT @JuliaSellerm:
4/14 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction... https://t.co/MzRw7YrSBr
RT @DrAkhilX: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/7mVGcElZsP https://t.co/jtywtHr…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 4 https://t.co/w4Vdko9woa
RT @DrAkhilX: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/7mVGcElZsP https://t.co/jtywtHr…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/7mVGcElZsP https://t.co/jtywtHrjPE
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/t4rWtCXe8F
Exciting overview of the upcoming tailored tools in HFpEF with Dr Rebecca Lane @BritishCardioSo #YiC2024 #Cardiotwitter #FINEARTS-HF #STEPHFpEF
RT @spcardio: “Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction” é o artigo destacado pelo Grupo de Estudo de…
RT @spcardio: “Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction” é o artigo destacado pelo Grupo de Estudo de…
“Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction” é o artigo destacado pelo Grupo de Estudo de Insuficiência Cardíaca (GEIC) no novo episódio do podcast. O Dr. João Agostinho, cardiologista e vogal do GEIC, e o Dr. Diogo Ferreira, interno de https://t.co/uC5ufNx6T3
RT @kmd_cardiology: ***Jounal club*** 「Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction」 N Engl J Med 2024 ;…
***Jounal club*** 「Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction」 N Engl J Med 2024 ; 391 : 1475 - 1485 HFmrEF/HFpEFに対するフィネレノンの効果 ~FINEARTS-HF trial~ https://t.co/WEDUEwfW9t
RT @DrVinodEndo: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t…
RT @Takatsuki_GIM: HFpEFに対するフィネレノン https://t.co/zBc4DZAyz1 P: EF>40%の心不全患者(40歳以上, NYHA Ⅱ-Ⅳ) I: フィネレノン投与 C: プラセボ O: 心不全イベント、心血管死の複合 ↓ 心…
HFpEFに対するフィネレノン https://t.co/zBc4DZAyz1 P: EF>40%の心不全患者(40歳以上, NYHA Ⅱ-Ⅳ) I: フィネレノン投与 C: プラセボ O: 心不全イベント、心血管死の複合 ↓ 心不全イベントRRは0.82(95% CI: 0.71-0.94, p=0.006) 心血管死HRは0.93(95% CI: 0.78-1.11)で有意差なし https://t.co/o89KMR3NvG
「フィネレノン半端ないって!HFpEF/HFmrEFでも、心不全転帰イベントの発生率が有意に低下やで!そんなんできひんやん普通!…でも、イベント発生率の絶対差は大きくなくて、臨床的意義には議論の余地あるし、高K血症増える点は慎重に評価せなあかんって~!」https://t.co/UnQkqGspti
RT @ringo710828: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/mwZKOvNYau
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/jobXZMiVLQ
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/wYH11ukRZT
RT @DrVinodEndo: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/ZgtryUFVO5 @drstak70 @DrSandeepRai2 @baxirahul @DrDeepakKrishn1 @serioustaurean @DrVinayak5555 @Nedu_MD @DrMarthaGulati @NeilSkolnik @purviparwani
RT @accpcardprn: The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart fa…
RT @accpcardprn: The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart fa…
RT @accpcardprn: The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart fa…
RT @FFayoubi: For updates https://t.co/KafHR5OqnK
https://t.co/QMbpGCcwJ9
RT @accpcardprn: The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart fa…
RT @accpcardprn: The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart fa…
For updates https://t.co/KafHR5OqnK
RT @accpcardprn: The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart fa…
The FINEARTS-HF trial investigated finerenone as a therapy in HFpEF and HFmrEF and found a reduction in worsening heart failure events. Is this an exciting breakthrough for these patients or just a more expensive me-too drug? #whatsnewwednesday https://t.co/dBGStfaIxW
RT @CajinaCarmen: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://…
【DrゆみのWeekly Journal Scan】 *HFpEF/HFmrEFへのMRAの効果 from NEJM* https://t.co/iuJ87ZG6RX
https://t.co/Uwhc3KNOza EF正常または軽度低下のある心不全に対してフィネレノンを使用し、心不全悪化によるすべての心血管系の原因による死亡の複合発生率をプラセボと比較して有意に低下させた。 HFpEFの管理は難しいですよね。一つ選択肢ができたのでは。
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/pvKM9ZYicq
#Clinicalquestion Will be interested to see if Finerenone is covered the community. Will predict it is not.. would rather utilize MRA (Spiro), which is effective and cheap. https://t.co/Ak6UNPgyHC @NEJM
ガイドラインを塗り替えるエビデンスがでた!HFpEFも新たな時代ですね。Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/u9n93rC1GD
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/mwZKOvNYau
RT @JWatch: Catch up on the latest #KidneyWk news from NEJM Group:
RT @drbennisahmed: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction finerenone resulted in a significantly l…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @JWatch: Catch up on the latest #KidneyWk news from NEJM Group:
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @JWatch: Catch up on the latest #KidneyWk news from NEJM Group:
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @JWatch: Catch up on the latest #KidneyWk news from NEJM Group:
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes https://t.co/ACWOXh6QNp
Catch up on the latest #KidneyWk news from NEJM Group:
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/rW2eoFVtvK
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
RT @NEJM: In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly r…
In the FINEARTS-HF trial, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction. Full trial results and Plain Language Summary: https://t.co/6CYFFJRbBZ https://t.co/8NFiVBRbqg
RT @MHcsba: New England Journal of Medicine (NEJM) 2024: FINEARTS-HF: Finerenona en IC con FEVI preservda o ligeramente disminuida *¿ Un "…
New England Journal of Medicine (NEJM) 2024: FINEARTS-HF: Finerenona en IC con FEVI preservda o ligeramente disminuida *¿ Un "TOPCAT"-like más convincente? DOI:10.1056/NEJMoa2407107 https://t.co/JXh5LxARgV
Link https://t.co/5pJjeyBZRb
RT @VipsMDMEd: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.c…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/BXlBTDnJ1V
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/OJY208jBxY
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/6k7l3xJxzZ
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
Study: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. https://t.co/iugox7GcCt
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/emwdCGbYbw
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
RT @NEJM: Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFF…
Original Article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) https://t.co/6CYFFJRbBZ Editorial: FINEARTS-HF — The Latest Masterpiece for MRAs in Heart Failure https://t.co/dquTfwTvKa #Cardiology https://t.co/MNUUnL4PBC
RT @edgarvlermamd: FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite…
RT @edgarvlermamd: FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite…
RT @edgarvlermamd: FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite…
RT @edgarvlermamd: FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite…
RT @edgarvlermamd: FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite…
RT @edgarvlermamd: FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite…
RT @edgarvlermamd: FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite…
FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite of total worsening heart failure events & death from CV causes vs. placebo ca. 2024 from @NEJM #Nephpearls #Cardiorenal
FINEARTS-HF: In patients w/ heart failure & HFmrEF/ HFpEF, finerenone resulted in a significantly ⬇️ rate of a composite of total worsening heart failure events & death from CV causes vs. placebo ca. 2024 from @NEJM #Nephpearls #Cardiorenal
RT @DrDamluji: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: @NEJM
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/A8UDSqWc8r
話題だったので遅ればせながら全文読みました。 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/EmdPP7sHoN
Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction https://t.co/hYn0g2gUIl via @practiceupdate
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
#循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/eTlY1FELYF PMID: 39225278
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
RT @Cardio_Pharm_JP: #循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildl…
#循薬ネット Web JC 2024年10月02日(水) 20:00 - 21:00 #Finerenone #フィネレノン #HFpEF 【対象論文】 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/eTlY1FFjOd PMID: 39225278
‼️ATENCIÓN ‼️ Este miércoles 18/09 no te pierdas el Ateneo Bibliográfico
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/MiIDgyBI6r
Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction https://t.co/rhl92K5AAo via @practiceupdate
RT @DrRazi4: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/5YnnMYH6BU
Los avances en tratamientos para pacientes con #insuficienciacardíaca no se detienen , este año la gran revelación #Finerenona. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. NEJM 2024 . DOI: 10.1056/NEJMoa24071 https://t.co/PjHAgoN8n3
Trend up+5: Solomon SD, ..., Finearts-hf Committees and Investigators (N Engl J Med) __Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction__ https://t.co/VITnO3STNr
2 min cardiology (臨床論文、担当:佐藤宏行) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction S D Solomon et al. NEJM September 1, 2024 https://t.co/reQ8eCCmTt #Cardiology #FINEARTS_HF →
RT @DrDanMO: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine https://t.co/…
【RCT】EF40%以上の心不全患者へのフィネレノン投与は、プラセボ投与と比較して、心不全悪化イベント(心不全による予定外の入院や再入院、緊急受診)、心血管死亡の複合転帰を減少させた。 #ペ読 https://t.co/rxLHEbuI5E
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. https://t.co/eFPefT0m64
RT @niiyan51: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/jMPL2Fb701
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://t.co/jMPL2Fb701
EC
SN
N
DS
SZ
FE
AM
RR
AH
L
TH
HR
PD
AM
AE
JO
LB
N
A
CM
D
L
NB
M
HR
A
MM
FE
NJ
NR
HH
HM
O
MV
NT
AO